Key facts
- Bloom biomedical’s last known valuation is $29.0M (Apr 2025).
- It has raised $9.0M; the latest was Early Stage VC ($9.0M) in Apr 2025.
- Notable investors include Device of Tomorrow Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Bloom biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Bloom biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bloom biomedical
Developer of a minimally invasive interbody fusion implantation technology platform designed to improve orthopedic surgical care. The company's platform provides a novel integrated bone access and resection system to approach joint spaces or skeletal targets with minimal disruption to surrounding soft tissue, enabling surgeons to enhance surgical efficiency, reduce procedural burden, and accelerate recovery, reducing patient trauma and preserving function.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2022
- Website
- bloombiomed.com/
- Ownership
- Privately Held (backing)
Bloom biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bloom biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bloom biomedical in its N-PORT filings yet. We sweep new filings monthly.